Skip to main content
Shenzhen Chipscreen Biosciences Co., Ltd. logo

Shenzhen Chipscreen Biosciences Co., Ltd. — Investor Relations & Filings

Ticker · 688321 ISIN · CNE100003LW0 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 967 across all filing types
Latest filing 2024-03-29 Audit Report / Informat…
Country CN China
Listing Shanghai Stock Exchange 688321

About Shenzhen Chipscreen Biosciences Co., Ltd.

https://www.chipscreen.com/en/

Shenzhen Chipscreen Biosciences Co., Ltd. specializes in the discovery and development of original small molecule innovative drugs. The company leverages its proprietary chemical genomics-based drug discovery and early evaluation platform to address unmet medical needs in oncology, metabolic diseases, and autoimmune disorders. Its portfolio includes Chidamide (Epidaza), a selective histone deacetylase (HDAC) inhibitor approved for peripheral T-cell lymphoma and advanced breast cancer, and Chiglitazar (Bilessyl), a novel PPAR pan-agonist for type 2 diabetes. Chipscreen Biosciences maintains an integrated R&D system covering drug discovery, clinical development, and commercialization, focusing on molecular mechanisms and translational medicine to provide novel therapeutic solutions.

Recent filings

Filing Released Lang Actions
公司关于会计师事务所履职情况的评估报告
Audit Report / Information Classification · 95% confidence The document is an evaluation report on the performance of the accounting firm KPMG Huazhen in auditing the company's 2023 annual financial report. It details the auditor's qualifications, the audit process, communication with the audit committee, and the overall assessment of the auditor's work. The document does not contain the actual audited financial statements or detailed financial data but rather an assessment of the auditor's performance and the audit process. It is a standalone audit-related report focusing on the audit firm's performance and compliance with auditing standards, which fits the definition of an Audit Report / Information (AR). The document length is 2077 characters, which is relatively short but contains substantive content about the audit process and evaluation, not just an announcement or certification. Therefore, the appropriate classification is AR with high confidence. FY 2023
2024-03-29 Chinese
2023年度独立董事述职报告（黎翔燕）
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director's Annual Report" for the year 2023 from Shenzhen Microcore Biotechnology Co., Ltd. It details the independent director's personal background, participation in board and committee meetings, communication with auditors and shareholders, oversight of financial reports, and overall evaluation of the company's governance and compliance during the year. The content focuses on the independent director's duties and observations rather than presenting full financial statements or audit results. The document length is 3216 characters, which is relatively short and more consistent with a report or statement rather than a full annual report or audit report. This type of document is typically classified under Board/Management Information (MANG) as it relates to governance and management oversight activities, specifically the independent director's report on their duties and observations for the year. It is not an Annual Report (10-K), Audit Report (AR), or Regulatory Filing (RNS) because it does not contain comprehensive financial data or audit opinions. Therefore, the best classification is MANG with high confidence.
2024-03-29 Chinese
2023年度财务审计报告
Audit Report / Information Classification · 100% confidence The document is titled "2023年度财务审计报告" which translates to "2023 Annual Financial Audit Report". It is issued by KPMG Huazhen LLP, a recognized audit firm, and contains detailed audit opinions, key audit matters, management responsibilities, and the auditor's responsibilities. The document includes comprehensive financial statements such as consolidated balance sheets, income statements, cash flow statements, and notes to the financial statements for the fiscal year ending December 31, 2023. The presence of detailed audit procedures, audit opinions, and full financial data indicates this is a standalone audit report rather than a full annual report or a brief announcement. The length of the document (15,000 characters) and the detailed content confirm it is not merely an announcement or certification. Therefore, the document fits the category of an Audit Report / Information (AR). FY 2023
2024-03-29 Chinese
关于2023年度利润分配方案的公告
Notice of Dividend Amount Classification · 95% confidence The document is an announcement regarding the 2023 profit distribution plan of Shenzhen Microchip Biotechnology Co., Ltd. It details the decision not to distribute cash dividends, not to issue bonus shares, and to roll over undistributed profits to the next year. It mentions the approval by the board and supervisory committee and that the plan will be submitted to the 2023 annual shareholders meeting for approval. The document is relatively short (2506 characters) and focuses on the dividend distribution plan rather than the full annual report or financial statements. This fits the definition of a Notice of Dividend Amount (DIV) as it announces dividend decisions and related shareholder meeting information.
2024-03-29 Chinese
关于使用自有美元资金进行现金管理的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Shenzhen Microchip Biotechnology Co., Ltd. regarding the use of its own idle US dollar funds for cash management. It details the board's approval of using up to 30 million USD for safe, liquid, and principal-guaranteed investment products for up to 12 months. The document includes the investment purpose, amount, product types, risk control measures, and supervisory opinions. It is a formal disclosure about a financing/capital management activity rather than a financial report, earnings release, or regulatory filing. The content fits best under Capital/Financing Update (CAP) as it concerns the company's capital management and investment of idle funds. The document length is about 2211 characters, which is consistent with an announcement rather than a full report. Therefore, the classification is CAP with high confidence.
2024-03-29 Chinese
独立董事提名人声明与承诺（罗勇根）
Board/Management Information Classification · 95% confidence The document is a nomination statement and commitment declaration for an independent director candidate at Shenzhen Microchip Biotechnology Co., Ltd. It details the qualifications, independence criteria, and compliance with relevant laws and regulations for the nominee. There is no financial data, no report or results, no meeting materials, no voting results, no legal proceedings, no capital changes, or other financial disclosures. It is a governance-related announcement about board member nomination and qualifications. Therefore, it fits best under Board/Management Information (MANG). The document length is short and focused solely on nomination and compliance statements, confirming it is not a full report or announcement of a report publication.
2024-03-29 Chinese

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.